ABSTRACT:

Pseudomonas aeruginosa has been known as an aerobic rod bacterium, with negative response to Gram staining, does not form spores. It is able to cause many types of infectious diseases human. Because of its tendency to cause infections in people with weakened immune systems, its adaptability, resistance to antibiotics, and the wide range of dynamic defense mechanisms it possesses, this organism is a very difficult thing to treat in modern medicine. This bacterial species is accountable for both hospital and community-acquired infections. They frequently cause hospital pneumonia and urinary tract infections. Pseudomonas aeruginosa contain various virulence factors like lipopolysaccharide (LPS), exoenzyme S and exotoxin a. aminoglycosides, cephalosporins and carbapenems are the first line of antibiotic therapy for P. aeruginosa infection. This article highlights the epidemiology, virulence factors, diagnosis and management of Pseudomonas aeruginosa.

REFERENCES :

1) Angeletti, S., Cella, E., Prosperi, M., Spoto, S., Fogolari, M., De Florio, L., Antonelli, F., Dedej, E., De Flora, C., Ferraro, E., Incalzi, R. A., Coppola, R., Dicuonzo, G., Francescato, F., Pascarella, S., & Ciccozzi, M. (2018). Multi-drug resistant Pseudomonas aeruginosa nosocomial strains: Molecular epidemiology and evolution. Microbial pathogenesis, 123, 233–241. https://doi.org/10.1016/j.micpath.2018.07.020 
2) Bassetti, M., Vena, A., Croxatto, A., Righi, E., & Guery, B. (2018). How to manage Pseudomonas aeruginosa infections. Drugs in context, 7, 212527. https://doi.org/10.7573/dic.212527
3) Curran, C. S., Bolig, T., & Torabi-Parizi, P. (2018). Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection. American journal of respiratory and critical care medicine, 197(6), 708–727. https://doi.org/10.1164/rccm.201705-1043SO
4) Flayyih, M. Yousif, H. and Subhi, I. (2013) Antimicrobial effects of black tea (Camellia sinensis) on Pseudomonas aeruginosa isolated from eye infection. Iraqi Journal of Science, 54(2): 255-265
5) Hassan, l. A. DarweeshM. F. & Hasan, T. H. (2023). The Immune-modulator Activity of Pseudomonas aeruginosa Extracted Protein: Azurin Charming Protein. Lat. Am. J. Pharm. 42 (special issue): 245-251
6) Hauser, A. R., Jain, M., Bar-Meir, M., & McColley, S. A. (2011). Clinical significance of microbial infection and adaptation in cystic fibrosis. Clinical microbiology reviews, 24(1), 29–70. https://doi.org/10.1128/CMR.00036-10
7) Horna, G., & Ruiz, J. (2021). Type 3 secretion system of Pseudomonas aeruginosa. Microbiological research, 246, 126719. https://doi.org/10.1016/j.micres.2021.126719
8) Kollef, M. H., & Burnham, C. D. (2017). Ventilator-Associated Pneumonia: The Role of Emerging Diagnostic Technologies. Seminars in respiratory and critical care medicine, 38(3), 253–263. https://doi.org/10.1055/s-0037-1599224
9) Makhnevich, A., Feldhamer, K. H., Kast, C. L., & Sinvani, L. (2019). Aspiration Pneumonia in Older Adults. Journal of hospital medicine, 14(7), 429–435. https://doi.org/10.12788/jhm.3154
10) Mulcahy, L. R., Isabella, V. M., & Lewis, K. (2014). Pseudomonas aeruginosa biofilms in disease. Microbial ecology, 68(1), 1–12. https://doi.org/10.1007/s00248-013-0297-x
11) Remold, S. K., Brown, C. K., Farris, J. E., Hundley, T. C., Perpich, J. A., & Purdy, M. E. (2011). Differential habitat use and niche partitioning by Pseudomonas species in human homes. Microbial ecology, 62(3), 505–517. https://doi.org/10.1007/s00248-011-9844-5
12) Reynolds, D., & Kollef, M. (2021). The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update. Drugs, 81(18), 2117–2131. https://doi.org/10.1007/s40265-021-01635-6
13) Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., Rochwerg, B., Rubenfeld, G. D., Angus, D. C., Annane, D., Beale, R. J., Bellinghan, G. J., Bernard, G. R., Chiche, J. D., Coopersmith, C., De Backer, D. P., … Dellinger, R. P. (2017). Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Critical care medicine, 45(3), 486–552. https://doi.org/10.1097/CCM.0000000000002255
14) Ribeiro, Á. C. D. S., Crozatti, M. T. L., Silva, A. A. D., Macedo, R. S., Machado, A. M. O., & Silva, A. T. A. (2019). Pseudomonas aeruginosa in the ICU: prevalence, resistance profile, and antimicrobial consumption. Revista da Sociedade Brasileira de Medicina Tropical, 53, e20180498. https://doi.org/10.1590/0037-8682-0498-2018
15) Rosenthal, V. D., Al-Abdely, H. M., El-Kholy, A. A., AlKhawaja, S. A. A., Leblebicioglu, H., Mehta, Y., Rai, V., Hung, N. V., Kanj, S. S., Salama, M. F., Salgado-Yepez, E., Elahi, N., Morfin Otero, R., Apisarnthanarak, A., De Carvalho, B. M., Ider, B. E., Fisher, D., Buenaflor, M. C. S. G., Petrov, M. M., Quesada-Mora, A. M., … Remaining authors (2016). International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: Device-associated module. American journal of infection control, 44(12), 1495–1504. https://doi.org/10.1016/j.ajic.2016.08.007
16) Slattery, W. H., 3rd, & Brackmann, D. E. (1996). Skull base osteomyelitis. Malignant external otitis. Otolaryngologic clinics of North America, 29(5), 795–806.
17) Subhi IM, Zgair AK, Ghafil JA. (2017) Extraction and Purification of Pseudomonas aeruginosa
18) Lipopolysaccharide Isolated from Wound Infection. World J Exp Biosci 5: 5 – 8.
19) Subhi IM. (2022) Pseudomonas aeruginosa lipopolysaccharide involves in inflammatory and autoimmune response in patients with rheumatoid arthritis. World J Exp Biosci 10: 32-37.
20) Tuon, F. F., Dantas, L. R., Suss, P. H., & Tasca Ribeiro, V. S. (2022). Pathogenesis of the Pseudomonas aeruginosa Biofilm: A Review. Pathogens (Basel, Switzerland), 11(3), 300. https://doi.org/10.3390/pathogens11030300
21) Wilson MG and Pandey S. (2013) Pseudomonas aeruginosa. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557831/